Medizinische Universität Graz - Research portal
Selected Publication:
Aringer, M; Graninger, WB.
Treating rheumatoid arthritis with new disease modifying drugs.
Acta Med Austriaca. 2002; 29(1):33-35
Doi: 10.1046/j.1563-2571.2002.01042.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Graninger Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Rheumatoid arthritis (RA) is a serious illness that can only be controlled by the appropriate use of disease modifying anti-rheumatic drugs (DMARDs). In spite of the successful use of such substances, and of methotrexate in particular, a large number of patients still experience disease progression. Leflunomide and the two anti-TNF agents, infliximab and etanercept, were therefore warmly greeted as very welcome additions to the rheumatologist's armamentarium. These successful newcomers, their strengths and problems are the focus of the present review.
- Find related publications in this database (using NLM MeSH Indexing)
- Adjuvants, Immunologic - therapeutic use
- Arthritis, Rheumatoid - drug therapy
- Humans -
- Isoxazoles - therapeutic use
- Tumor Necrosis Factor-alpha - antagonists and inhibitors
- Find related publications in this database (Keywords)
- DMARD therapy
- leflunomide
- infliximab
- etanercept
- methotrexate